Global Ion Channel Modulators Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Ion Channel Modulators Market Research Report 2024
According to Mr Accuracy reports’s new survey, global Ion Channel Modulators market is projected to reach US$ 14100 million in 2034, increasing from US$ 11510 million in 2024, with the CAGR of 2.9% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Ion Channel Modulators market research.
Key companies engaged in the Ion Channel Modulators industry include Pfizer, Inc.(US), Neusentis, Inc.(US), AstraZeneca(UK), Aurora Biomed, Inc.(Canada), CalciMedica, Inc.(US), Cellectricon AB(Sweden), Convergence Pharmaceuticals Limited(UK), Cytocentrics AG(Germany) and Evotec AG(Germany), etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % value of Ion Channel Modulators were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Ion Channel Modulators market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Ion Channel Modulators market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Pfizer, Inc.(US)
Neusentis, Inc.(US)
AstraZeneca(UK)
Aurora Biomed, Inc.(Canada)
CalciMedica, Inc.(US)
Cellectricon AB(Sweden)
Convergence Pharmaceuticals Limited(UK)
Cytocentrics AG(Germany)
Evotec AG(Germany)
flyion GmbH(Germany)
GlaxoSmithKline Plc.(UK)
Nanion Technologies GmbH(Germany)
NeuroSearch A/S(Denmark)
Novartis AG(Switzerland)
Parion Sciences, Inc.(US)
Sanofi(France)
Targacept, Inc.(US)
Xention Limited(UK)
Zalicus, Inc.(US)
Segment by Type
Channel Blockers
Channel Openers
Clinical Trials
Hospital
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Ion Channel Modulators report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Key companies engaged in the Ion Channel Modulators industry include Pfizer, Inc.(US), Neusentis, Inc.(US), AstraZeneca(UK), Aurora Biomed, Inc.(Canada), CalciMedica, Inc.(US), Cellectricon AB(Sweden), Convergence Pharmaceuticals Limited(UK), Cytocentrics AG(Germany) and Evotec AG(Germany), etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % value of Ion Channel Modulators were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Ion Channel Modulators market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Ion Channel Modulators market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer, Inc.(US)
Neusentis, Inc.(US)
AstraZeneca(UK)
Aurora Biomed, Inc.(Canada)
CalciMedica, Inc.(US)
Cellectricon AB(Sweden)
Convergence Pharmaceuticals Limited(UK)
Cytocentrics AG(Germany)
Evotec AG(Germany)
flyion GmbH(Germany)
GlaxoSmithKline Plc.(UK)
Nanion Technologies GmbH(Germany)
NeuroSearch A/S(Denmark)
Novartis AG(Switzerland)
Parion Sciences, Inc.(US)
Sanofi(France)
Targacept, Inc.(US)
Xention Limited(UK)
Zalicus, Inc.(US)
Segment by Type
Channel Blockers
Channel Openers
Segment by Application
Clinical Trials
Hospital
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Ion Channel Modulators report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source